STAT3 and neoplasm: Recently, JAK antagonist pacritinib, when used in combination with TMZ, elicited GSC-specific cytotoxicity and chemo-sensitization via regulating the JAK2/STAT3 axis in human GBM tumor initiating cells implanted in mouse brains, which eventually improved survival [227].